Close Menu

NEW YORK (GenomeWeb) – Owlstone Medical today announced it has raised $15 million for the commercialization of its breath-based diagnostic technology.

The financing was led co-led by Horizon Ventures, and Aviva Ventures, and includes follow-on investments from other existing backers of Owlstone, the Cambridge, UK-based company said. The funding will allow it to bring its test called Breath Biopsy to market, continue ongoing trials for the technology across multiple cancers, and further grow its precision medicine services to the drug development industry.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.


This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.